tiprankstipranks
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
Company Announcements

Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options

Don't Miss Our Christmas Offers:

Ocuphire Pharma (OCUP) has issued an announcement.

Ocuphire Pharma, Inc. has engaged board director Dr. Jay Pepose as a consultant, compensating him with a monthly fee of $39,583, 32,000 restricted stock units, and options for 48,000 shares at $1.79 each. These incentives will vest over a year, incentivizing Dr. Pepose’s continued involvement with the company until the Consulting Agreement’s end date of April 11, 2025, signaling strategic moves that may interest stock market enthusiasts.

For an in-depth examination of OCUP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTwo new option listings and one option delisting on October 24th
TheFlyOcuphire Pharma price target lowered to $10 from $18 at Canaccord
TheFlyOcuphire Pharma rating placed under review at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App